Multi-CBV Vaccine for Type 1 Diabetes Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for type 1 diabetes are ineffective due to limited understanding of enterovirus serotypes involved, with existing technologies unable to effectively prevent or treat the disease as they fail to account for the complex interactions and variations among the numerous enterovirus serotypes.
Innovation Solution
A vaccine comprising inactivated Coxsackie B virus (CBV) serotypes CBV1, CBV2, CBV3, CBV4, CBV5, and CBV6, or their components/antibodies, which induce cross-protection against multiple serotypes, addressing the diabetogenic potential and immune response variability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a vaccine covering all 100 enterovirus serotypes is developed, then comprehensive protection against type 1 diabetes is achieved, but the device complexity and manufacturing feasibility become unrealistic with current standard vaccine technologies
Solution Approach 1:
The patent segments the 100 enterovirus serotypes into distinct groups (polioviruses, coxsackie A viruses, coxsackie B viruses, echoviruses, and numbered enteroviruses) and develops separate vaccine compositions for each group. This segmentation makes the vaccine development and manufacturing feasible while still providing comprehensive protection through targeted coverage of each serotype group.
2Ease of manufacture
If only a limited number of enterovirus serotypes are included in the vaccine, then the manufacturing and implementation becomes feasible, but the protection coverage against type 1 diabetes becomes incomplete
Solution Approach 1:
The patent creates multi-functional vaccine compositions where each vaccine formulation addresses multiple enterovirus serotypes within a specific group. For example, the vaccine includes inactivated polioviruses (serotypes 1, 2, and 3), coxsackie A viruses (serotypes 2, 4, 6, 9, 16), coxsackie B viruses (serotypes 1-6), echoviruses (serotypes 3, 4, 6, 9, 11, 22, 30), and numbered enteroviruses (serotypes 7, 16, 33, 48, 71). This multi-functionality ensures comprehensive protection while maintaining manufacturing feasibility.
3Reliability
If the vaccine includes multiple enterovirus serotypes with different diabetogenic potentials, then comprehensive immune protection is achieved, but the immune response variability and difficulty in determining effective serotype combinations increases
Solution Approach 1:
The patent employs different inactivation methods and formulations for different enterovirus serotype groups to optimize immune response. Each serotype group is processed with parameters tailored to its specific characteristics, such as using formalin inactivation for polioviruses and heat inactivation for coxsackie viruses. This parameter optimization ensures consistent and effective immune protection across all serotypes while managing immune response variability.
Data Source
AI summary
The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.